News | November 13, 2024
Hikal Q2 FY25 revenue stood at Rs. 453 Cr
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Subscribe To Our Newsletter & Stay Updated
